Overview

Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

Status:
RECRUITING
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II.
Phase:
PHASE3
Details
Lead Sponsor:
KalVista Pharmaceuticals, Ltd.
Treatments:
sebetralstat